Nasal transcriptomics characterize T-helper (T)2-low asthma endotypes in a study of Puerto Rican and Dominican adults living in the U.S.
This study utilized nasal transcriptomics to identify five distinct asthma endotypes in Puerto Rican and Dominican adults, revealing that non-T2-high profiles are prevalent in this population and that the T1-high profile is strongly associated with severe asthma exacerbations.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Asthma is often thought of as a single condition, a wheezing breath that responds to a standard set of medicines. Yet for many people, the standard treatments fail to work, leaving them vulnerable to severe attacks. Scientists have long known that the immune system, the body's defense force, can malfunction in different ways to cause this breathing trouble. In the past, researchers focused heavily on one specific type of immune cell, known as a T-helper 2 cell, which drives inflammation in many patients. This understanding led to the development of targeted therapies that block this specific pathway. However, this focus left a gap in knowledge for the many patients whose symptoms do not fit this pattern. If the immune system is misfiring in a different way, treating it as if it were the same type of error will not help. To truly personalize care, doctors need a map of the different ways asthma can manifest, especially in populations that have been historically underrepresented in medical research.
A new study turns to the nose to draw this map, looking at the genetic activity inside nasal cells to sort asthma into distinct groups. The research team focused on adults of Puerto Rican and Dominican descent living in the United States, a group known to suffer from high rates of severe asthma. By examining the "signature genes" that turn on or off in the nasal lining, the researchers could see which immune pathways were active in each person. They were looking for the signals of three main types of immune cells: the well-known T2 cells, as well as T1 and T17 cells, which had been studied less in this context. The goal was to see if these genetic patterns could define specific types of asthma, or endotypes, and to understand who falls into which category.
The study followed hundreds of adults in New York and Chicago, comparing those with asthma to those without. When the scientists analyzed the genetic activity in the nasal samples of the asthma patients, they found that the group was not a single block of similar cases. Instead, the data revealed five distinct genetic profiles. Only a small fraction of the patients, about five percent, showed the classic T2-high pattern that responds to current targeted drugs. The majority fell into other categories. One large group, representing nearly a third of the patients, showed high activity in the T17 pathway. Another significant group, about a quarter of the total, showed low activity across all three major immune pathways, a state the researchers call T2-low. There were also groups with high T1 activity, and a mixed group with high activity in both T1 and T17 pathways.
The researchers then looked to see what factors pushed a person into one of these specific groups. They found that a patient's background and health history were strong predictors of their genetic profile. Being of Puerto Rican descent was linked to a higher likelihood of having the T17-high profile compared to being of Dominican descent. Being female was associated with several of the non-T2 profiles, including the T1-high and the mixed T1-T17 groups. Furthermore, patients who also had a diagnosis of chronic obstructive pulmonary disease, or COPD, were much more likely to have one of the non-T2 patterns. These findings suggest that the standard view of asthma, which often centers on the T2 pathway, does not capture the reality for many of these patients.
Perhaps the most striking finding concerned the severity of the disease. The study tracked the patients over a year to see who suffered severe asthma attacks. The data showed that patients with the T1-high genetic profile were far more likely to experience these severe exacerbations than those with other profiles. This specific group faced a risk of severe attacks that was more than four times higher than the others. The study confirmed these genetic patterns in a separate group of adults of African ancestry, suggesting that these findings are robust and not just a fluke of one specific group.
The implications of this work are significant for how asthma is understood and treated. The study identifies that a large portion of the asthma population, particularly women and people of Puerto Rican heritage, likely have a type of the disease driven by immune pathways other than the classic T2 route. Because current specialized treatments are designed to block the T2 pathway, these patients are effectively left without a specific therapy for their underlying cause. The research highlights that the disease is more diverse than previously thought and that the people most at risk for severe attacks may be the very ones whose specific immune profile is being overlooked. By using nasal genetic testing to sort patients into these five distinct groups, doctors may one day be able to match treatments to the specific engine driving a patient's asthma, rather than applying a one-size-fits-all approach.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.